Literature DB >> 12217747

The impact of positive peritoneal washings and serosal and adnexal involvement on survival in patients with stage IIIA uterine cancer.

Oliver Preyer1, Andreas Obermair, Elisabeth Formann, Werner Schmid, Lewis C Perrin, Bruce G Ward, Alexander J Crandon, James L Nicklin.   

Abstract

OBJECTIVE: The aim of this study was to determine the prognostic significance of serosal involvement (SER), adnexal involvement (ADN), and positive peritoneal washings (PPW) in patients with Stage IIIA uterine cancer. We also sought to determine patterns of recurrence in patients with this disease.
METHODS: The records of 136 patients with Stage IIIA uterine cancer treated at the Queensland Centre for Gynecological Cancer between March 1983 and August 2001 were reviewed. One hundred thirty-six patients underwent surgery and 58 (42.6%) had full surgical staging. Seventy-five patients (55.2%) had external beam radiotherapy and/or brachytherapy postoperatively. Overall survival was the primary statistical endpoint. Statistical analysis included univariate and multivariate Cox models.
RESULTS: Forty-six patients (33.8%) had adnexal involvement, 23 (16.9%) had serosal involvement, and 40 (29.4%) had positive peritoneal washings. Median follow-up was 55.1 months (95% confidence interval, 36.9 to 73.4 months) after which time 71 patients (52.2%) remained alive. For patients with endometrioid adenocarcinoma, ADN and SER were associated with impaired survival on multivariate analysis (odds ratio 2.8 and 3.2, respectively). In the subgroup of patients with high-risk tumors (including papillary serous carcinomas, clear cell carcinomas, and uterine sarcomas), neither ADN, nor SER, nor PPW influenced survival.
CONCLUSION: Patients with Stage IIIA uterine cancer constitute a heterogeneous group. For patients with endometrioid adenocarcinoma, both ADN and SER, but not PPW, were associated with impaired prognosis. For patients with high-risk histological types, prognosis is poor for all three factors.

Entities:  

Mesh:

Year:  2002        PMID: 12217747     DOI: 10.1006/gyno.2002.6744

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  Positive peritoneal cytology is an independent risk-factor in early stage endometrial cancer.

Authors:  Gunjal Garg; Feng Gao; Jason D Wright; Andrea R Hagemann; David G Mutch; Matthew A Powell
Journal:  Gynecol Oncol       Date:  2012-09-29       Impact factor: 5.482

2.  Outcome of Endometrial Cancer Stage IIIA with Adnexa or Serosal Involvement Only.

Authors:  Jan J Jobsen; Lambert Naudin Ten Cate; Marnix L M Lybeert; Astrid Scholten; Elzbieta M van der Steen-Banasik; Job van der Palen; Marika C Stenfert Kroese; Annerie Slot; Eltjo M J Schutter; Sabine Siesling
Journal:  Obstet Gynecol Int       Date:  2011-05-04

3.  Long-term survival of endometrioid endometrial cancer patients.

Authors:  Leszek Gottwald; Piotr Pluta; Janusz Piekarski; Michał Spych; Katarzyna Hendzel; Katarzyna Topczewska-Tylinska; Dariusz Nejc; Robert Bibik; Jerzy Korczyński; Aleksandra Ciałkowska-Rysz
Journal:  Arch Med Sci       Date:  2010-12-29       Impact factor: 3.318

4.  Positive peritoneal cytology in early-stage endometrial cancer does not influence prognosis.

Authors:  P-M Tebeu; Y Popowski; H M Verkooijen; C Bouchardy; F Ludicke; M Usel; A L Major
Journal:  Br J Cancer       Date:  2004-08-16       Impact factor: 7.640

5.  Revaluating the survival effects of International Federation of Gynecology and Obstetrics 1988 stage IIIA criteria for endometrial cancer.

Authors:  Osman Türkmen; Alper Karalok; Derman Başaran; Günsu Kimyon; Gizem Kul; Gökhan Tulunay; Işın Üreyen; Taner Turan
Journal:  J Turk Ger Gynecol Assoc       Date:  2017-09-01

6.  Impact of peritoneal cytology on survival of endometrial cancer patients treated with surgery and radiotherapy.

Authors:  P M Tebeu; G Y Popowski; H M Verkooijen; J Casals; F Lüdicke; G Zeciri; M Usel; C Bouchardy; A L Major
Journal:  Br J Cancer       Date:  2003-12-01       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.